Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vivos Therapeutics (VVOS) Leases (2021 - 2025)

Vivos Therapeutics (VVOS) has disclosed Leases for 5 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Leases rose 199.65% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 199.65% increase, with the full-year FY2024 number at $1.0 million, down 25.49% from a year prior.
  • Leases was $3.4 million for Q3 2025 at Vivos Therapeutics, up from $3.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.4 million in Q3 2025 to a low of $516000.0 in Q4 2021.
  • A 5-year average of $1.6 million and a median of $1.4 million in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: soared 228.49% in 2022, then tumbled 31.11% in 2023.
  • Vivos Therapeutics' Leases stood at $516000.0 in 2021, then skyrocketed by 228.49% to $1.7 million in 2022, then decreased by 18.29% to $1.4 million in 2023, then dropped by 25.49% to $1.0 million in 2024, then skyrocketed by 227.81% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Leases are $3.4 million (Q3 2025), $3.2 million (Q2 2025), and $951000.0 (Q1 2025).